myeloma
Celgene gets FDA licence extension for myeloma drug
February 19, 2015Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma
The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …
Celgene’s blood cancer pill too expensive for NHS
February 13, 2015Sales and Marketing Celgene, NHS, NICE, Pomalidomide, imnovid, myeloma
NICE has decided not to recommend Celgene’s Imnovid for treating patients with multiple myeloma – a cancer that affects white …
Treatment shifts away from chemotherapy for multiple myeloma
December 10, 2014Research and Development, Sales and Marketing Kyprolis, carfilzomib, chemotherapy, myeloma, onyx pharmaceuticals
Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …
Priority review for Novartis myeloma drug
November 26, 2014Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac
Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …
Future bleak for Novartis’ myeloma drug
November 21, 2014Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat
Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …
The numbers game: getting quantitative information to patients
November 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kadcyla, Les Rose, clinical, myeloma, numbers, numerics
The great physicist Lord Kelvin said: “If you can measure something, and express it in numbers, then you know something …
More cancer patients surviving for longer
October 31, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, bladder, breast, myeloma, oncology, ons, prostate
Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …
Amgen cancer drug fails key test
August 14, 2014Sales and Marketing Amgen, Cancer, Kyprolis, myeloma
Amgen’s new rare cancer drug has failed in a late-stage trial just a year after the US biotech spent $10.4 …
Scottish Medicines Consortium disappoints Celgene
July 8, 2014Sales and Marketing Celgene, SMC, Scottish Medicines Consortium, imnovid, myeloma
Celgene admitted it is ‘disappointed’ with the Scottish Medicines Consortium decision not to recommend blood cancer therapy Imnovid for patients …
BMS and AbbVie get FDA lift
May 21, 2014Research and Development, Sales and Marketing AbbVie, BMS, FDA, elotuzumab, multiple, myeloma
Bristol-Myers Squibb and AbbVie are celebrating after receiving breakthrough designation status from the US regulator for their investigational medicine elotuzumab …
How can ‘innovation’ be defined?
April 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, NHS, UK, eric low, innovation, myeloma
Innovation has been and continues to be an important topic of discussion for a number of different stakeholders and disciplines …
Celgene ‘stops Mylan entering market’
April 6, 2014Sales and Marketing Celgene, Mylan, Revlimid, myeloma
Generic manufacturer Mylan is suing Celgene in a spat over allowing copycat versions of existing cancer drugs – Revlimid and …
NICE approves Velcade
March 21, 2014Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma
NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …
Regulate, don’t strangulate
January 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, code of practise, low, myeloma
As many of you will know, work is now under way to revise the ABPI Code. Not before time I …
Trials and tribulations
October 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, eric low, myeloma, transparency
I have been chief executive of Myeloma UK since its inception 17 years ago, and its unique bedside to bench …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
